1. Approved for 12-week use. Reglan is only approved to be taken for up to 12 weeks, though it’s often prescribed for longer time periods.
2. Generic name is Metoclopramide. Check your prescription label as you may in fact be taking a generic version of Reglan, but not be aware that you are.
3. Prescribed for more than Acid Reflux (GERD). Reglan is a gastrointestinal stimulant, but it’s also an anti-nauseant. It’s prescribed for Gastroesophageal Reflux Disease, Diabetic Gastroparesis (Diabetic Gastric Stasis), and Renal or Hepatic Impairment.
4. Linked to Tardive Dyskinesia. Reglan has been linked to Tardive Dyskinesia, which involves abnormal and involuntary repetitive movement. Tardive dyskinesia is often permanent, and there is no known effective treatment.
On Raptiva? Then the clock’s ticking. Your pharmacy will only give you a refill on your prescription till until Monday, June 8th. While we’re happy that Genentech decided to voluntarily withdraw Raptiva from the market given the drug’s link to the deadly progressive multifocal leukoencephalopathy (PML) infection, there’s one thing Genentech couldn’t take away: patients’ stress.
Think about it-you’re on Raptiva for psoriasis and you’ve been told that stopping Raptiva at once could either worsen your psoriasis or, worse yet, necessitate hospitalization. That’ll give you pause if you’re considering going cold turkey. But then again, you did receive that letter in the mail from Genentech advising you that you’ll need to stop taking it. Feeling caught between a rock and a hard place? You should be.
But before you stress yourself out even more, see your doctor first. You and your doctor need to come up with a plan to switch to another psoriasis treatment before coming off Raptiva. Beyond that (as if that isn’t enough), if you any questions about what recourse you may have as a result of being on Raptiva and being told you need to come off it pronto, you may want to ask a lawyer about your situation.
It’s uncomfortable and worrisome enough having to go through screening for colon cancer through colonoscopy—which is extremely important in identifying and treating the disease. Now add one more concern to deter people from getting the procedure: Oral Sodium Phosphate (OSP) as a bowel cleanser has been associated with acute kidney injury. C.B. Fleet Company announced a voluntary recall of its OTC products: Fleet(R) Phospho-soda(R) and Fleet(R) Phospho-soda(R) EZ-Prep(R) Bowel Cleansing System, and the FDA is slapping a black box warning on other OSPs, as well as recommending that only prescription OSPs be used by patients for bowel cleansing prior to undergoing colonoscopy.
Researchers set out to determine exactly which parts of the colonoscopy process deterred patients from getting the procedure and, you guessed it, not wanting to take the bowel prep ranked as the No. 1 deterrent. But all OSPs are not created equally; for example, one report says that NutraPrep did the job just as well, if not better than OSPs. And it isn’t associated with kidney injury. So if you’re scheduled for a colonoscopy, ask your health provider about alternative bowel cleansers.
This week, journalist Philip Dawdy reported on the popular website Furious Seasons that Wyeth’s Effexor me-too drug Pristiq, FDA approved in early 2008, had already generated 1,272 adverse event reports in the FDA’s MedWatch system through the end of 2008, and wrote with live links to the reports:
“It’s discouraging that 17 of those reports involve completed suicides through the end of 2008. There are also 48 reports of suicidal ideation through the end of 2008.”
“That’s a lot in such a short period of time, especially considering that this drug isn’t exactly widely used,” Dawdy points out. Read the rest of this entry »
On May 19, 2009, researchers presented a study that found children who received the trivalent inactivated influenza vaccine [TIV] had a three times greater risk of hospitalization for the flu than kids who were not vaccinated at the International Conference of the American Thoracic Society in San Diego.
To determine whether the vaccine was effective in reducing the number of hospitalizations over consecutive flu seasons for 8 years, the researchers conducted a study of 263 children between the ages of 6 months and 18, evaluated at the Mayo Clinic between 1996 and 2006, with laboratory-confirmed influenza and reviewed records to determine which kids had received a flu shot before the illness and hospitalization. Read the rest of this entry »